+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2025

  • ID: 4802093
  • Report
  • Region: Global
  • 100 pages
  • Infinium Global Research
UP TO OFF
until Dec 31st 2019
1 of 3

FEATURED COMPANIES

  • Achillion Pharmaceuticals
  • Akari Therapeutics
  • Apellis Pharmaceuticals
  • F. Hoffmann-La Roche AG
  • Novartis AG
  • Other Comp
  • MORE
The report on the global paroxysmal nocturnal hemoglobinuria (PNH) treatment market provides qualitative and quantitative analysis for the period from 2017 to 2025. The report predicts the global paroxysmal nocturnal hemoglobinuria (PNH) treatment market to grow with a CAGR of 11.6% over the forecast period from 2019-2025. The study on paroxysmal nocturnal hemoglobinuria (PNH) treatment market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2017 to 2025.

The report on paroxysmal nocturnal hemoglobinuria (PNH) treatment market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global paroxysmal nocturnal hemoglobinuria (PNH) treatment market over the period of 2017 to 2025. Moreover, the report is a collective presentation of primary and secondary research findings.

Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global paroxysmal nocturnal hemoglobinuria (PNH) treatment market over the period of 2017 to 2025. Further, Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.

Report Findings
1) Drivers
  • The rising number of blood and bone marrow related disorders
  • Development in stem cell research
2) Restraints
  • High costs associated with medical treatment and adverse side effects with existing treatments
3) Opportunities
  • The unmet demand for drugs in developing countries
Research Methodology

A) Primary Research
The primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include
1. Key Opinion Leaders associated with the author
2. Internal and External subject matter experts
3. Professionals and participants from the industry
The primary research respondents typically include
1. Executives working with leading companies in the market under review
2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/ country managers
5. Vice President level executives.

B) Secondary Research
Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. Each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include
1. Company reports and publications
2. Government/institutional publications
3. Trade and associations journals
4. Databases such as WTO, OECD, World Bank, and among others.
5. Websites and publications by research agencies

Segment Covered
The global paroxysmal nocturnal hemoglobinuria (PNH) treatment market is segmented on the basis of diagnostic test, and treatment.

The Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market by Diagnostic Test
  • Complete Blood Count Test (CBC)
  • Lactate Dehydrogenase Test (LDH)
  • Bone Marrow Examination
  • Urine Test for Hemosiderin
  • Flow Cytometry
  • Other Tests
The Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market by Treatment
  • Medication
  • Stem Cell Transplant
  • Blood Transfusion
Company Profiles

The companies covered in the report include
  • F. Hoffmann-La Roche AG
  • Akari Therapeutics
  • Alexion Pharmaceuticals, lnc.
  • Ra Pharmaceuticals
  • Novartis AG
  • Alnylam Pharmaceuticals, Inc.
  • Apellis Pharmaceuticals
  • Achillion Pharmaceuticals
  • Regeneron Pharmaceuticals, Inc.
  • Other Companies
What does this report deliver?
1. Comprehensive analysis of the global as well as regional markets of the paroxysmal nocturnal hemoglobinuria (PNH) treatment market.
2. Complete coverage of all the segments in the paroxysmal nocturnal hemoglobinuria (PNH) treatment market to analyze the trends, developments in the global market and forecast of market size up to 2025.
3. Comprehensive analysis of the companies operating in the global paroxysmal nocturnal hemoglobinuria (PNH) treatment market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
4. Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Achillion Pharmaceuticals
  • Akari Therapeutics
  • Apellis Pharmaceuticals
  • F. Hoffmann-La Roche AG
  • Novartis AG
  • Other Comp
  • MORE
1. Preface
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches

2. Executive Summary
2.1. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Highlights
2.2. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Projection
2.3. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Regional Highlights

3. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. Porter's Five Forces Analysis
3.4. Growth Matrix Analysis
3.4.1. Growth Matrix Analysis by Diagnostic Test
3.4.2. Growth Matrix Analysis by Treatment
3.4.3. Growth Matrix Analysis by Region
3.5. Value Chain Analysis of Paroxysmal Nocturnal Hemoglobinuria Treatment Market

4. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Macro Indicator Analysis

5. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market by Diagnostic Test
5.1. Complete Blood Count Test (CBC)
5.2. Lactate Dehydrogenase Test (LDH)
5.3. Bone Marrow Examination
5.4. Urine Test for Hemosiderin
5.5. Flow Cytometry
5.6. Other Tests

6. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market by Treatment
6.1. Medication
6.2. Stem Cell Transplant
6.3. Blood Transfusion

7. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market by Region 2019-2025
7.1. North America
7.1.1. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market by Diagnostic Test
7.1.2. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market by Treatment
7.1.3. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market by Country
7.2. Europe
7.2.1. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market by Diagnostic Test
7.2.2. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market by Treatment
7.2.3. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market by Country
7.3. Asia-Pacific
7.3.1. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market by Diagnostic Test
7.3.2. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market by Treatment
7.3.3. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market by Country
7.4. RoW
7.4.1. RoW Paroxysmal Nocturnal Hemoglobinuria Treatment Market by Diagnostic Test
7.4.2. RoW Paroxysmal Nocturnal Hemoglobinuria Treatment Market by Treatment
7.4.3. RoW Paroxysmal Nocturnal Hemoglobinuria Treatment Market by Sub-region

8. Company Profiles and Competitive Landscape
8.1. Competitive Landscape in the Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market
8.2. Companies Profiles
8.2.1. F. Hoffmann-La Roche AG
8.2.2. Akari Therapeutics
8.2.3. Alexion Pharmaceuticals, lnc.
8.2.4. Ra Pharmaceuticals
8.2.5. Novartis AG
8.2.6. Alnylam Pharmaceuticals, Inc.
8.2.7. Apellis Pharmaceuticals
8.2.8. Achillion Pharmaceuticals
8.2.9. Regeneron Pharmaceuticals, Inc.
8.2.10. Other Companies

9. Appendix
9.1. Primary Research Findings and Questionnaire
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • F. Hoffmann-La Roche AG
  • Akari Therapeutics
  • Alexion Pharmaceuticals, lnc.
  • Ra Pharmaceuticals
  • Novartis AG
  • Alnylam Pharmaceuticals, Inc.
  • Apellis Pharmaceuticals
  • Achillion Pharmaceuticals
  • Regeneron Pharmaceuticals, Inc.
  • Other Comp
Note: Product cover images may vary from those shown
Adroll
adroll